Drugs / HuCNS-SC cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01632527 | Jun 2012 → Jun 2015 | age-related macular degeneration | StemCells, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HuCNS-SC cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01632527 ↗ |
| Modality | Cell therapy | “HuCNS-SC cells will be transplanted by a board-certified vitreoretinal surgeon.” NCT01632527 ↗ |
| Route | Other | “The HuCNS-SC cells will be administered into the subretinal space through a standard surgical approach.” NCT01632527 ↗ |